Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Use of Metronomic Chemotherapy in Hormone Receptor‐Positive/ HER2 ‐Negative Metastatic Breast Cancer: A Retrospective Multicenter Study. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.annonc.2021.09.019
10.1016/j.annonc.2021.09.019 · External reference
10.1158/1078‐0432.ccr‐21‐2947
10.1158/1078‐0432.ccr‐21‐2947 · External reference
First‐ and Second‐Line Treatment Strategies for Hormone‐Receptor (HR)‐Positive HER2‐Negative Metastatic Breast Cancer: A Real‐World Study
10.1016/j.breast.2021.02.015 · 2021 · External reference
10.1200/jco.24.00248
10.1200/jco.24.00248 · External reference
10.1016/s1470‐2045(21)00034‐6
10.1016/s1470‐2045(21)00034‐6 · External reference
10.1056/nejmoa2214131
10.1056/nejmoa2214131 · External reference
10.2217/fon.12.49
10.2217/fon.12.49 · External reference
Elacestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
10.1200/jco.22.00338 · 2022 · External reference
10.1093/annonc/mdz012
10.1093/annonc/mdz012 · External reference
10.1016/j.annonc.2020.08.2098
10.1016/j.annonc.2020.08.2098 · External reference
10.1200/jco.2024.42.17_suppl.lba1000
10.1200/jco.2024.42.17_suppl.lba1000 · External reference
10.1016/s0140‐6736(23)01245‐x
10.1016/s0140‐6736(23)01245‐x · External reference
Less Is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice
10.1172/jci9872 · 2000 · External reference
Inhibition of CD4+25+ T Regulatory Cell Function Implicated in Enhanced Immune Response by Low‐Dose Cyclophosphamide
10.1182/blood-2004-06-2410 · 2005 · External reference
Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil as First‐Line Chemotherapy for Advanced Breast Cancer
10.1200/jco.2010.33.9101 · 2011 · External reference
Efficacy and Safety of Low‐Dose Metronomic Chemotherapy With Capecitabine in Heavily Pretreated Patients With Metastatic Breast Cancer
10.1016/j.ejca.2011.06.040 · 2012 · External reference
Low‐Dose Metronomic Oral Administration of Vinorelbine in the First‐Line Treatment of Elderly Patients With Metastatic Breast Cancer
10.3816/cbc.2010.n.039 · 2010 · External reference
Safety and Efficacy Study of Metronomic Vinorelbine, Cyclophosphamide Plus Capecitabine in Metastatic Breast Cancer: A Phase II Trial
10.1016/j.canlet.2017.01.027 · 2017 · External reference
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor‐Positive, ERBB2‐Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA‐II Randomized Clinical Trial
10.1001/jamaoncol.2023.2150 · 2023 · External reference
Efficacy of Subsequent Treatments in Patients With Hormone‐Positive Advanced Breast Cancer Who Had Disease Progression Under CDK 4/6 Inhibitor Therapy
10.1186/s12885-023-10609-8 · 2023 · External reference
Systemic Therapies Following Progression on First‐Line CDK4/6‐Inhibitor Treatment: Analysis of Real‐World Data
10.1093/oncolo/oyac075 · 2022 · External reference
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor‐Positive, ERBB2‐Negative Metastatic Breast Cancer
10.1001/jamanetworkopen.2024.61067 · 2025 · External reference
Capecitabine Efficacy After Cycline‐Dependent‐Kinase 4/6 Inhibitor Plus Endocrine Therapy in Metastatic Hormone Receptor‐Positive Breast Cancer
10.1016/j.ctarc.2023.100738 · 2023 · External reference
10.1056/nejmoa2407086
10.1056/nejmoa2407086 · External reference
